medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Analytical approaches for antimalarial antibody responses to confirm historical and recent malaria transmission in malaria-endemic areas in the Philippines

Maria Lourdes M. Macalinao[1,2,3], Kimberly M. Fornace[2,4], Ralph A. Reyes[1], Alison Paolo N. Bareng[1], Tom Hall[2], John H. Adams[5], Christèle Huon[6], Chetan E. Chitnis[6], Jennifer S. Luchavez[1], Kevin K. A. Tetteh[2], Katsuyuki Yui[3,7], Julius Clemence R. Hafalla[2], Fe Esperanza J. Espino[1], Chris J. Drakeley[2*]

[1]Department of Parasitology and National Reference Centre for Malaria and Other Parasites, Research Institute for Tropical Medicine, Department of Health, Muntinlupa City, Philippines; [2]Faculty of Infectious Tropical Diseases, Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; [3]School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan; [4]Institute of Biodiversity, Animal Health & Comparative Medicine, University of Glasgow, Glasgow, United Kingdom; [5]University of South Florida, Tampa, FL, 33612, USA; [6]Malaria Parasite Biology and Vaccines Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France, [7]Shionogi Global Infectious Diseases Division, Institute of Tropical Medicine, Nagasaki University

*For correspondence: Chris.Drakeley@lshtm.ac.uk (CJD)

Abstract

Assessing the status of malaria transmission in endemic areas becomes increasingly challenging as countries approach elimination and infections become rare. Here, we evaluated the use of multiplex antibody response data to malaria-specific antigens to classify recent and historical infections of differentially exposed populations in three provinces in the Philippines. We utilized samples (n=9132) from health-facility based cross-sectional surveys in Palawan (ongoing malaria transmission), Occidental Mindoro (limited transmission), and Bataan (no transmission) and quantified antibody responses against 8 *Plasmodium falciparum* and 6 *P. vivax*-specific antigens. Different statistical and machine learning analytical methods were used to examine associations between antigen-specific antibody responses with malaria incidence, and the ability to predict recent or historical exposure. Consistent with the provinces' endemicity status, antibody levels and seroprevalence were consistently highest in Palawan and lowest in Bataan. A machine learning (ML) approach (Random Forest model) using identified responses to 4 antigens (PfGLURP R2, Etramp5.Ag1, GEXP18 and PfMSP1$_{19}$) gave better predictions for *P. falciparum* infection (positive by microscopy, RDT and/or PCR) or likely recent exposure in Palawan (AUC: 0.9591, CI 0.9497-0.9684) than mixture models calculating seropositivity to individual antigens. Meanwhile, employing the same ML approaches for the vivax-specific antigens did not improve predictions for recent *P. vivax* infections. Still, the antigen panel was overall able to confirm the absence of recent exposure to *P. falciparum* and *P. vivax* in both Occidental Mindoro and Bataan through single and ensemble ML approaches. Seroprevalence and seroconversion rates based on cumulative exposure markers AMA1 and MSP1$_{19}$ showed accurate trends of historical *P. falciparum* and *P. vivax* transmission in the 3 sites. Our study emphasizes the utility of serological markers in predicting recent and historical exposure in a sub-national elimination setting, establishes baseline antibody data for monitoring risk in malaria-endemic areas in the Philippines, and also highlights the potential use of machine learning models using multiplex antibody responses to accurately assess the malaria transmission status of countries aiming for elimination.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

The Philippines is aiming to eliminate malaria by 2030 following a sub-national elimination approach **(World Health Organization, 2014)**. The country had more than 70% decrease in malaria cases in the past decade, with only 2 provinces reporting local cases; 19 provinces are in elimination phase, and the remaining 60 declared malaria-free in 2021. *Plasmodium falciparum* (Pf) contributes more than 80% to the total malaria cases, *P. vivax* (Pv) is at >20%, while the other species *P. malariae, P. ovale* and *P. knowlesi* make up <1% of the cases **(World Health Organization, 2019)**. As the number of areas still reporting local cases continue to decrease, assessing the malaria levels in endemic areas and differentiating areas with residual transmission becomes increasingly challenging. Innovative tools that are capable of detecting both past and present infections can be used to confirm the presence or absence of malaria transmission in endemic areas supporting sub national specific control approaches **(Drakeley et al., 2005; malERA Refresh Consultative Panel, 2017; World Health Organization and Global Malaria Programme, 2017)**.

Several studies have utilized serology and malaria-specific antibody responses to estimate malaria transmission intensities **(Folegatti et al., 2017; Fowkes et al., 2010)**, showing that these represent a viable additional metric of both historical and recent exposure **(van den Hoogen et al., 2015; Idris et al., 2017; Kerkhof et al., 2016; Pothin et al., 2016; Ssewanyana et al., 2017; Wu et al., 2020a)**. Antibody prevalence alone and as age-adjusted seroconversion rates correlate with entomological and parasitological measures used in estimating malaria transmission **(Corran et al., 2007; Niass et al., 2017; Stanisic et al., 2015)**. Many of the original studies examined single antigen platforms and antigens associated with cumulative exposure to infection such as Pf apical membrane antigen-1 (PfAMA1) and the 19KDa fragment of Pf merozoite protein 1 ($PfMSP1_{19}$). More recent advances in array and bead-based assay platforms allow for simultaneous analysis of antibody responses to multiple antigens **(Fouda et al., 2006; Kerkhof et al., 2016; Koffi et al., 2015; Ondigo et al., 2012; Perraut et al., 2014; Wu et al., 2019)** . These approaches increase assay throughput and allow the inclusion of multiple targets that can represent diversity in the parasite and allow for variation in individual immune response. Recent multi-antigen studies have identified markers associated with antibody responses describing recent and historical *P. falciparum* and *P. vivax* exposure **(Helb et al., 2015; van den Hoogen et al., 2015; Longley et al., 2020; Wu et al., 2020b)**. To fully realize the additional information provided by examining multiple antigenic targets, these studies have employed more advanced statistical approaches and algorithms such as machine learning to predict optimal combinations of antibody responses for the outcome of interest.

The overall aim of this study was to evaluate known malaria-specific *P. falciparum* and *P. vivax* serological markers for their predictive capacity to distinguish current or recent infections from historically exposed individuals in order to better describe malaria endemicity in three areas of the Philippines. Specifically, we sought to evaluate different approaches to determining seropositivity for estimating malaria transmission intensities and exposure in areas of varying endemicity. To achieve this, we: 1) measured malaria-specific antibody responses in participants recruited through health facility surveys in 3 sites in the Philippines, 2) evaluated analysis methods to determine seropositivity using single and multiple antigens, and 3) analyzed antibody responses and estimated transmission intensities in relation to the supposed immune status of these populations. Our findings detailing the antibody responses to multiple malaria-specific antigens demonstrate the utility of serology in showing the heterogeneity of malaria transmission in malaria-endemic populations in the Philippine setting.

Methods

Ethical approval

This study was reviewed and approved by the Research Institute for Tropical Medicine – Institutional Review Board (RITM IRB 2016-04) and LSHTM Research Ethics Committee (11597).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Study Sites and Samples

The study was conducted in 3 municipalities in 3 provinces in the Philippines, representing areas of varying malaria endemicity 1) Rizal in the province of Palawan, which is currently the most endemic area in the Philippines, and reported more than 60% of the total cases in the country (annual parasite index (API) of 5.7 per 1,000 risk population) in 2018; 2) Abra de Ilog, Occidental Mindoro, a municipality reporting sporadic local cases at the time of the survey and with declining transmission (API of 0.38 in 2018); and 3) Morong in Bataan with a last reported indigenous case in 2011 and declared malaria-free in 2019 (Figure 1).



Figure 1. Map showing the study sites, with red areas as the focused municipalities within the provinces marked yellow.

Participants were recruited from June 2016 to June 2018 in a health facility-based rolling cross-sectional survey detailed in Reyes et al **(2021)**. Briefly, all consulting patients, as well as their companions, were invited to participate and provide a finger-pricked blood sample for malaria diagnosis through microscopy (blood smear), rapid diagnostic test (RDT), and a dried blood spot sample on Whatman 3MM CHR filter paper for malaria diagnosis by PCR and serological analysis. The DBS samples were air-dried and stored in resealable bags with desiccant at 4°C while in the field, and transported at ambient temperatures to the laboratory facility, where it was stored at 4°C and −20°C for short- and long-term storage, respectively. A total of 9,132 DBS samples (6572 for Palawan, 1683 for Occidental Mindoro, and 877 for Bataan) were available for analysis for this study.

Multiplex bead-based assay of malaria-specific antibodies

Serological analysis was conducted using a multiplex bead-based assay as previously described **(Coutts et al., 2017; Helb et al., 2015; van den Hoogen et al., 2020b)**, with an antigen panel that included 8 *P. falciparum*-specific and 6 *P. vivax*-specific recombinant antigens coupled to Magplex beads (Luminex Corp, Austin, TX, USA). The antigens were PfAMA1 (apical membrane antigen 1), $PfMSP1_{19}$ (merozoite surface protein), and their *P. vivax* homologues PvAMA1 and $PvMSP1_{19}$; PfGLURP R2 (glutamate rich protein), Etramp5.Ag1 (early transcribed membrane protein 5), PfSEA1 (schizont egress antigen), GEXP18 (Gametocyte exported protein 18), MSP2 CH150/9 (CH150/9 allele of MSP2), MSP 2 Dd2 (Dd2 allele of MSP2), PvEBP (erythrocyte binding protein), PvRBP1a (reticulocyte binding protein 1a), PvRII and PvDBPRII (region II, Duffy binding protein). Antigen characteristics are shown in Table 1.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. List of antigens in the multiplex bead-based assay panel

Antigen	Description	Gene ID	Reference
Pf-specific			
PfAMA1	apical membrane antigen 1	PF3D7_1133400	Collins et al., 2007
$PfMSP1_{19}$	19 kDa fragment of merozoite surface protein (MSP) 1	PF3D7_0930300	Burghaus and Holder, 1994
PfGlurp R2	glutamate rich protein R2	PF3D7_1035300	Theisen et al., 1995
Etramp5.Ag1	early transcribed membrane protein 5	PF3D7_0532100	van den Hoogen et al., 2019; Spielmann et al., 2003
PfSEA1	schizont egress antigen	PF3D7_1021800	Raj et al., 2014
GEXP18	Gametocyte exported protein 18	PF3D7_0402400	Helb et al., 2015
MSP2 CH150	CH150/9 allele of MSP2	PF3D7_0206800	Polley et al., 2006
MSP2 Dd2	Dd2 allele of MSP2	PF3D7_0206800	Taylor et al., 1995
Pv-specific			
PvAMA1	apical membrane antigen 1	PVX_092275	Chuquiyauri et al., 2015
$PvMSP1_{19}$	merozoite surface protein	PVX_099980	França et al., 2016b
PvRII	region II, Duffy binding protein	PVX_110810	França et al., 2016a
PvDBP RII	region II, Duffy binding protein	PVX_110810	Ntumngia et al., 2012
PvEBP	erythrocyte binding protein	PVX_110835	Hester et al., 2013; Menard et al., 2013
PvRBP 1a	reticulocyte binding protein 1a	PVX_098585	França et al., 2016a

The assay was conducted as described in Wu et al (**2019**). Briefly, serum was eluted from DBS samples (~1uL from 3mm punch) with overnight incubation on a shaker and used at final dilution of 1:400. Approximately 1000 beads per antigen were added per well in 96-well flat bottom plates, and were washed using a handheld magnetic washer (Bio-Plex®) before adding 50uL of the eluted serum samples and controls, which included 2 positive controls for *P. falciparum* and *P. vivax* (pool of plasma from adults in a hyperendemic malaria setting), and 1 negative control (European malaria-naïve blood donors). After 1.5 hours on a shaker, plates were washed three times with PBS-T buffer, and 50uL of 1:200 secondary antibody (Jackson Immuno 109-116-098: Goat anti-human Fcy-fragment specific IgG conjugated to R-Phycoerythrin (R-PE) was added before a further 1.5-hour incubation. After washing, samples were read using the Luminex 200 machine and net median fluorescence intensity (MFI) levels to all antigens were recorded for all samples. Plate specific adjustments were performed based on the outcome of standard control curves generated from positive control pools included on each plate.

Data analysis

Statistical analyses were performed using R version 3.6.3 and Graphpad Prism 8. IgG antibody responses recorded as net MFI values were analyzed using different methods. Quantitative continuous antibody response data (reported as $\log_{10}$ MFI values) were analyzed in relation to clinico-epidemiological data, and compared for different groups (*i.e.*, by age group, study site or current malaria infection) using Student's t-test or one-way ANOVA Kruskal-Wallis test with Wilcoxon test for pairwise comparisons. Correlations between the levels of antibody responses as well as age and malaria positivity were analyzed using Spearman's rank correlation.

Determining seropositivity rates using single antigen responses

Binary outcomes for seropositivity to each antigen were determined through the computation of cut-off values in 2 ways: by using *a.)* a 2-component finite mixture model (FMM), and *b.)* a reference naïve/ negative population (NegPop; mean MFI plus three standard deviations). The FMM was computed using the mixEM

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

function in R mixtools package, where the model identifies a negative component by modelling the log MFI of the entire dataset as two normally distributed populations and identifying a threshold value from the modelled negative population (mean MFI plus three standard deviations). To evaluate the accuracy of these classifications, we used samples from different known exposed and unexposed populations as validation data (Table 2). The validation data included a *P. falciparum* and *P. vivax*-positive group with African positive controls, as well as clinical samples from a Malaysia study **(Fornace et al., 2019)** and this study. The malaria-negative group consisted of European malaria-naïve samples, and Philippine malaria-negative samples from individuals under 10 years of age in a 2017 cross-sectional study in Bataan **(van den Hoogen et al., 2020a)** and this study. For the negative population model, the European samples were used as reference population. Samples were considered seropositive for specific antigens if MFI values are higher than the antigen cutoff values (mean MFI plus 3 standard deviations for each antigen). Sensitivity and specificity for identifying current *P. falciparum* and *P. vivax* infection from this study and the validation dataset, as well as receiver operating characteristics (ROC) curves were determined for the seropositivity results of each antigen from this approach (Supplementary Tables 1 and 2).

Applying machine learning techniques for multiplex analysis of antigen responses

Additionally, we evaluated supervised classification approaches utilizing data from multiple antigen responses. We used machine learning techniques to assess the predictive ability of all or combinations of antigens for determining recent and historical malaria exposure. The 8 Pf-specific antigens were the covariates evaluated for *P. falciparum* exposure, along with age. For predicting *P. vivax* exposure, the 6 Pv-specific antigens were used as the covariates. Age data was not available for all the *P. vivax* training data, and was therefore excluded. The training data used for these models, as detailed in Table 2, included the validation dataset described, and to account for the observed age-dependent cumulative responses to the antigens, the negative dataset included historical positives, which are data from survey participants aged 50 years and older from Malaysia and Philippines (assumed to have had some historical exposure), as well as a random selection of Pf or Pv-negatives from all age groups from this current study. The historical positives were used as the positive training dataset for historical exposure, and the negative population training data included the same negatives from the validation dataset.

Super Learner (SL) optimized with AUC (Area under the ROC Curve) was used as an ensemble modelling algorithm to allow for evaluating multiple models simultaneously **(Helb et al., 2015; Hubbard et al., 2013)**, namely Random Forest (RF), k-Nearest Neighbor (kNN), generalized boosted models (GBM), Support Vector Machine (SVM), and GLM with Lasso (glmnet). Feature selection with corP, that screens for univariate correlation, was also included for some component models (GBM, RF). The SL model gives a prediction value that ranges from 0 to 1, and this can be used to obtain binary classification (*i.e.*, those with prediction values higher than 0.5 were considered positive). A 20-fold cross-validation was performed for internal validation to evaluate the performance of the fitted SL models using a portion of the training dataset withheld from the model, and the whole training dataset. ROC curves were used to evaluate the outcome of predicted values for the samples and were then compared to the single antigen performances. The performance of each ML model, or base learner, in the SL ensemble was also assessed. For additional assessment of the model performance, external validation was performed for the classification models through an independent dataset from a Malaysia cross-sectional survey **(Fornace et al., 2018)**, which used the same panel of *P. falciparum* antigens (not available for *P. vivax* panel).

Evaluating model performance in identifying current Pf and Pv infections in this study

Antibody responses to antigens included in this study (in particular, PfGLURP R2, Etramp5.Ag1 and GEXP18) have been previously shown to be predictive of recent exposure to *P. falciparum* infection **(Helb et al., 2015;**

Table 2. Training and validation data used in the classification models

Training data used	N	Validation dataset *	Negative population model	SuperLearner / Random Forest: Recent Pf exposure	SuperLearner / Random Forest: Recent Pv exposure	SuperLearner / Random Forest: Historical Pf exposure	Random Forest Historical Pf exposure	Random Forest Historical Pv exposure
European naive controls	179	**neg**	−	−	−	−	−	−
Positive controls								
African *P. falciparum*-positive	4	**Pf+**		+				
African *P. vivax*-positive	10	**Pv+**			+			
This study								
P. falciparum-positive subset	568	**Pf+**		+				
P. vivax microscopy-positive subset	46	**Pv+**			+			
Below 10 y.o. from Bataan	202	**neg**		−	−	−	−	−
Historical positives aged ≥50y.o. from Occidental Mindoro and Palawan	711			−		+		
PfAMA1 and PfMSP1$_{19}$ seropositive subset	512						+	
PvAMA1 and PvMSP1$_{19}$ seropositive subset	324							+
Randomly selected malaria-negatives from Palawan aged <50y.o.**	550			−	−			
Bataan study (van den Hoogen et al., 2020a)								
Below 10 y.o. from Bataan	73	**neg**		−	−	−	−	−
Malaysia study (Fornace et al., 2019)								
P. falciparum-positive subset	17	**Pf+**		+				
P. vivax-positive subset	37	**Pv+**			+			
Historical positives aged ≥50y.o. from Malaysia 2	1581					+		
PfAMA1 and PfMSP1$_{19}$ seropositive subset	1479			−			+	
PvAMA1 and PvMSP1$_{19}$ seropositive subset	873			−				+

* Finite mixture models (FMM) were derived from the entire ENSURE dataset (n=9132), and indicated validation dataset was used to determine receiver operating characteristics (ROC) curves for both FMM and Negative population models (seropositivity classifications from single antigens). For the supervised classification models, + means it was classified as positive for the model, and ─ means it is considered for negative classification. Abbreviations: Pf- P. falciparum, Pv- P. vivax, neg – malaria-negative; y.o.-years old

198

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

van den Hoogen et al., 2020c) and thus we assessed their performance using the malaria-positive samples in this study (n=889). In addition to single antigens, the SL algorithm was used to generate predictive outcomes based on different combinations of the covariates. The importance of the antigens in providing accurate predictions were assessed by using 3 to 9 covariates at a time for the SL model (based on the variable influence reported by the base learners used). The AUC values from the ROC analysis based on training data and ENSURE malaria-positives data were compared among the single-antigen seropositivity rates and machine learning predictions for recent exposure. For the *P. vivax* analysis, responses to all 6 antigens were evaluated as covariates. With Super Learner giving weights to multiple ML models assessed simultaneously, we also employed for classification the individual ML models that were given the most weight or importance, namely RF and GBM.

Estimating seroconversion rates and historical exposure

In line with previous studies, seropositivity of the cumulative exposure markers (AMA1, $MSP1_{19}$ for both *P. falciparum* and *P. vivax*) were used to estimate seroconversion rates (SCR), or the rate at which seronegative individuals become seropositive, and seroreversion rates (SRR), or the rate at which seropositive individuals revert to being seronegative, by fitting the age-specific prevalence in each of the 3 study sites into reverse catalytic models using likelihood ratio methods **(Drakeley et al., 2005; Sepúlveda et al., 2015)**. Seroprevalence data were fitted to models that allow for a change in SCR, and this was preferred if the likelihood ratio tests result in a significant change when compared to a model assuming constant SCR. The predicted time of change in transmission is then analyzed. In addition to the AMA1 and $MSP1_{19}$ seroprevalence based on FMM models, Random Forest classifications using the combined continuous data of AMA1 and $MSP1_{19}$ net MFI values for both *P. falciparum* (Pf-RF:2-covar) and *P. vivax* (Pv-RF:2-covar) were also used to generate seroprevalence curves used for the analysis. The positive training data used for these RF models are subsets of the historical positives that were seropositive to both markers for each species based on FMM cutoff values (Table 2). The Super Learner approach was also used to predict Pf and Pv historical exposure using quantitative data from all the antigens, with analysis performed separately for each species.

Results

Heterogeneity of antibody responses from the 3 collection sites

A total of 9132 samples from a health facility-based survey conducted from 2016 to 2018 **(Reyes et al., 2021)** were available for serological evaluation, with the majority (>70%) from Rizal, Palawan, where the monthly sampling spanned 2 years, while collection in the other sites Morong, Bataan and Abra de Ilog, Occidental Mindoro spanned 1 year. Females comprised more than 60% of the total number of participants, with higher proportions in Bataan and Occidental Mindoro, though individuals from all ages and gender groups were represented (Table 3).

Malaria infections were detected only in Palawan with ~50% of infections in participants of both sexes aged under 10 years old (51.8% and 48.2% males and females, respectively). Of the 889 *Plasmodium*-positive samples confirmed through either microscopy, RDT and/or PCR, 58.0% had *P. falciparum*, 12.4% had *P. vivax*, 6.7% had mixed Pf+Pv infections, 6.1% had *P. malariae*, *P. ovale* and *P. knowlesi*, while species identification could not be confirmed for 16.8% of the PCR-positive samples. From the Pf and Pv malaria-positive individuals (n=707, including mixed infections), 388 (54.8%) had fever before or during the visit to the health facility, 62.1% of which were aged 10 years and under. Conversely, 63.1% of the asymptomatic malaria infections were in individuals above 10 years old.

Firstly, we compared the magnitude of antibody responses to *P. falciparum* and *P. vivax* antigens from the 3 collection sites. Corroborating with the reported case prevalence in the area, we show that individuals

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

from Palawan consistently had the highest antibody levels to all antigens and in all age groups, followed by individuals from Occidental Mindoro then Bataan (Fig 2A, Supplementary Figure 1).

Table 3. Characteristics of study population by site

	Morong, Bataan		Abra de Ilog, Occidental Mindoro		Rizal, Palawan	
Number of analyzed samples	**877**		**1683**		**6572**	
Female, %	**628**	**(71.6%)**	**1101**	**(65.4%)**	**3734**	**(56.8%)**
Age, median (IQR)	**26**	**(11-39)**	**28**	**(15-43)**	**13**	**(5-31)**
number (% in site)						
0 to 5	150	(17.1%)	150	(8.9%)	1900	(28.9%)
6 to 10	63	(7.2%)	154	(9.2%)	1055	(16.1%)
11 to 19	102	(11.6%)	234	(13.9%)	957	(14.6%)
20 to 34	279	(31.8%)	508	(30.2%)	1222	(18.6%)
35 up	283	(32.3%)	637	(37.8%)	1438	(21.9%)
Plasmodium-positive by microscopy/RDT/PCR (% in site)*	**0**	**(0.0%)**	**0**	**(0.0%)**	**889**	**(13.5%)**
P. falciparum-positive (by microscopy/RDT/PCR)*	**0**	**(0.0%)**	**0**	**(0.0%)**	**595**	**(9.1%)**
P. vivax-positive (by microscopy/RDT/PCR)*	**0**	**(0.0%)**	**0**	**(0.0%)**	**172**	**(2.6%)**
PCR-confirmed species ID, n (% in site)						
P. falciparum, Pf mono-infection	0	(0.0%)	0	(0.0%)	516	(7.9%)
P. vivax, Pv mono-infection	0	(0.0%)	0	(0.0%)	110	(1.7%)
Pf + Pv mixed infection	0	(0.0%)	0	(0.0%)	60	(0.9%)
Other species (mono- or mixed infections)	0	(0.0%)	0	(0.0%)	55	(0.8%)
With fever or history of fever (% in site)	**69**	**(7.9%)**	**172**	**(10.2%)**	**2727**	**(41.5%)**
Symptomatic Pf and Pv infections*	0	(0.0%)	0	(0.0%)	388	(5.9%)
Asymptomatic infections (no fever, *Plasmodium*-positive)*	**0**	**(0.0%)**	**0**	**(0.0%)**	**428**	**(6.5%)**
Asymptomatic microscopy-positive Pf infections	0	(0.0%)	0	(0.0%)	132	(2.0%)
Asymptomatic microscopy-positive Pv infections	0	(0.0%)	0	(0.0%)	35	(0.5%)

* Numbers include all *Plasmodium* infections detected by microscopy, RDT and/or PCR. Some samples did not have enough material for further species identification by PCR, for which results were based on microscopy and/or RDT diagnosis, while some (n=149) were confirmed *Plasmodium*-positive only. Pf and Pv numbers reported include mixed infections, which were specified in the PCR-confirmed species ID breakdown.
** All 5 *Plasmodium* species, including *P. malariae* (n=50), *P. ovale* (n=4) and *P. knowlesi* (n=1), were detected in Palawan, with some as co-infections with Pf and/or Pv.

While antibody levels increased with age in all sites, there were marked differences observed between sites. Younger age groups from Bataan and Occidental Mindoro had similar magnitude for antigens Etramp5.Ag1, PvAMA1, PvMSP1$_{19}$ and PvDBPRII, which were significantly lower than in individuals from Palawan ($p<0.001$). The association between antibody levels and age as well as malaria positivity was then assessed for each antigen for the Palawan population, and expectedly, those associated with cumulative exposure PfAMA1, PfMSP1$_{19}$, PfGLURP R2, PvAMA1 and PvMSP1$_{19}$ were strongly correlated with age (Spearman's coefficient >0.5, $p<0.0001$), while those associated with recent exposure to *P. falciparum*, Etramp5.Ag1 and GEXP18, were less strongly associated (Spearman's coefficient of 0.39 and 0.42, respectively, $p<0.0001$), along with other *P. vivax* markers (Figure 2B). Strong positive correlations in antibody responses to all antigens were observed (Figure 2B), but the highest associations were between responses to antigens from the same species. For the *P. falciparum*-specific antigens, Etramp5.Ag1, PfGLURP R2 and GEXP18 had the stronger

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

associations with current *P. falciparum* infection (Spearman's correlation coefficient ranging from 0.26 to 0.27, p<0.0001), and PvMSP1$_{19}$ and PvDBPRII showed weak correlation (Spearman's coefficient of 0.13 and 0.12, respectively, p<0.0001) for current *P. vivax* infection.

Similarly, mean antibody levels were higher in a species-specific manner (Figure 3); Etramp5.Ag1, PfGLURP R2 and GEXP18 showed significantly higher antibody levels in those with active Pf infections (p<0.0001) and PvMSP1$_{19}$ antibody levels were highest in *P. vivax*-positive cases (p<0.001), with better resolution in younger age groups. Taken together, our results confirm the applicability of these serological markers in differentiating areas of varying malaria endemicity, and there were species-specific associations with current infection.



Figure 2. Antibody responses to serological markers of *P. falciparum* and *P. vivax* correlate with malaria incidence

A. Antibody levels (reported as log10 MFI) in response to *P. falciparum* cumulative and recent exposure markers PfAMA1, PfMSP1$_{19}$, and Etramp5.Ag1, and *P. vivax* serological markers PvAMA1, PvMSP1$_{19}$ and PvDBP.RII by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

B. Spearman's correlation coefficients for age, malaria diagnosis (Mal+: Plasmodium-positive, Pf+: *P. falciparum*-positive, Pv+: *P. vivax*-positive), and antibody responses to the 14 antigens in the panel for Palawan samples (n=6572).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. Serological markers exhibit species-specific association with current infection in varying levels
A-B) Comparison of antibody titers of Palawan samples (n=6572) for *Plasmodium*-positive (Pf: P. falciparum-positive, Pf/Pv: Pf and Pv mixed infection, Pv: P. vivax-positive) and negative (neg) samples by age group in each *P. falciparum*-specific (A) and *P.vivax*-specific antigen.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Identifying markers of recent falciparum and vivax malaria exposure and current infection

Next, we applied different analytical approaches to ascertain whether the serological markers can be used to predict recent or historical exposure. We first assessed the performance of responses to single antigens in determining binary outcomes for seropositivity by estimating cutoff values using finite mixture models (FMM) and negative population models that represented unsupervised and supervised classification models, respectively (Figure 4A & 4B, Supplementary Tables 1 & 2). Seropositivity results were then compared with *P. falciparum* and *P. vivax* positivity, as assessed by microscopy, RDT or PCR. The resulting seropositivity cutoff values were comparable for both models, with AUC values from the validation data ranging from 0.812 to 0.932 for the 8 *P. falciparum* markers, and 0.534 to 0.943 for the 6 *P. vivax* markers.

When evaluated in classifying study samples, AUC values ranged from 0.497 to 0.756 for *P. falciparum* markers and 0.513 to 0.731 for *P. vivax* markers, showing low predictive ability for some of the markers, although previously reported recent exposure markers Etramp5.Ag1 and GEXP18 for *P. falciparum* and $PvMSP1_{19}$ for *P. vivax,* had significantly higher AUC values (>0.735, $p<0.002$) compared to the rest of the markers analyzed (ranged from 0.4971 to 0.7065) (Supplementary Tables 1 & 2). Density plots of antibody responses also show an overlap in samples from malaria-negative and positive individuals, contributing to the lower AUCs (Supplementary Figure 2) though overall seropositivity to antigens matched with 79.2% of the falciparum-positive and 60% of the vivax-positive cases in the project dataset. Proportions of samples seropositive to at least 4 of the 8 Pf markers and at least 3 of 6 Pv markers were 5.02% and 5.70% for Bataan, 30.96% and 25.85% for Occidental Mindoro, and 53.90% and 40.03% for Palawan, respectively. Seroprevalence rates for all antigens were consistently low in Bataan in all age groups as shown in Figures 4A & 4B, with recent exposure markers (hollow circles) estimating lower rates, consistent with their lower correlation with age and lower likelihood of exposure to infection in this setting.

To analyze the multi-antigen continuous antibody data, we used supervised machine learning methods for antibody responses to antigens for both species. The Super Learner (SL) ensemble machine learning algorithm was used to simultaneously evaluate machine learning models, which included Random Forest (RF), k-Nearest Neighbor (kNN), generalized boosted models (GBM), Support Vector Machine (SVM), and GLM with Lasso (glmnet), in predicting recent and historical malaria exposure through the resulting weights applied to each learner after cross-validation. Different combinations of covariates were assessed for their relative importance for the model using the ROC curves of the cross-validated predictions (Figure 4C & 4D; Supplementary Tables 1 & 2). A 9-covariate model (SL: 9-covar) was evaluated for the Pf panel, which had the antibody responses to 8 antigens and age as covariates. This model had the highest AUC among all SL models, with a value of 0.9898 (95% CI 0.9874-0.9921) and 0.9197 (95% CI 0.9093-0.9302) for the binary classification predictions for the training data and test data, respectively. It was able to correctly identify 71.1% of the *P. falciparum*-positive individuals from this study (Supplementary Table 1). Removing the age as covariate (SL:8-covar model) decreased the prediction capacity of the model for the test data, with 53.3% of the *P. falciparum* infections identified. For predicting *P. vivax* recent exposure, *i.e.*, confirmed Pv infections, the 6 Pv antigens were used as covariates for the SL model (SL:6-covar) and had a resulting AUC of 0.8857 (95% CI 0.8429-0.9284) and 0.6332 (0.5979-0.6686) for validation data and test data, respectively (Supplementary Table 2).

Super Learner assigns weights to each machine learning model included in the ensemble algorithm after cross-validation, and for both Pf and Pv exposure predictions, generalized boosted models with or without feature selection (GBM and GBM_corP) were given the highest weights, followed by 3 included variations of the RF model (RF, RF-ranger and RF-ranger_corP) (Supplementary Figure 3A & 3B). However, upon using 20-fold nested cross-validation and closer inspection of the classification accuracy of the individual learners, the Random Forest (RF) models were found to have the highest AUCs for predicting *P. falciparum* recent infections in both the validation data (not shown) and test data (Supplementary Figure 3C), while component

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. Analysis of serological markers through machine learning methods improves classifications for recent *P. falciparum* and *P. vivax* exposure or current infection

A-B. Seropositivity rates of sample population by site and age group based on cutoff values from finite mixture models (FMM) and negative population model (NegPop) for Pf and Pv antigens (detailed in **Supplementary Tables 1 and 2**). Hollow dots represent the FMM and Negpop seropositivity rates for the two reported recent exposure markers Etramp5.Ag1 and GEXP18 for Pf (A), and PvMSP1$_{19}$ and PvDBP.RII for Pv (B) panel. Lines with error bars represent median with 95% CI.

C-D. Receiver operating characteristic (ROC) curves for the antibody responses to single antigens for individual antigens, and for the SL models (shown in both as binary outcomes of seropositivity / prediction values).

E-F. Variable importance of the 8 Pf-specific (E) and 6 Pv-specific (F) antigens based on the Random Forest model.

G. Predicted rates of recent Pf exposure based on analysis of the continuous antibody responses of the 8-antigen panel using Super Learner. Each hollow dot represents differences in the number of covariates used for the model (3, 4, 8, 9), as well as 2 showing rates from prediction values of the Random Forests (RF) component model (RF.covar4 and RF.covar8 in solid dots).

H. Predicted rates of recent Pv exposure based on analysis of the continuous antibody responses of the 6-antigen panel using Super Learner. Dots represent the positivity rates from the prediction values of the SL model, and the individual predictions from the 2 most weighted base learners in the resulting model – RF and GBM. RF predictions (RF.covar6) are shown as solid dots.

(SL: Super Learner, RF: random Forest, covar#: number of covariates included in the model, FMM: finite mixture models; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 with significance assessed by one-way ANOVA followed by Tukey's multiple comparison)

models for classifying vivax malaria infections had similar AUCs, ranging from 0.701 to 0.8 for test data (Supplementary Figure 3D).

The Super Learner ensemble model did not show any increase in classification accuracy compared to RF, which suggests that RF is the best performing model in distinguishing current or recent falciparum malaria infections. Still, both SL and SL-RF (RF prediction within the SL ensemble) predictions from the Pf panel had highly improved AUCs compared to single antigen classifications based on finite mixture models (Figure 4C), while model predictions for the Pv panel had comparable AUCs, and machine learning models did not improve the AUC predictions (Figure 4D). Variable importance in the RF model shows that responses to Etramp5.Ag1, PfGLURP R2, GEXP18 and PfMSP1$_{19}$ had the highest influence in the predictions for *P. falciparum* positivity (Figure 4E), while PvMSP1$_{19}$ and PvAMA1 were the most predictive *P. vivax* antigens (Figure 4F). Using the top 3 antigens (SL:3-covar - PfGLURP R2, Etramp5.Ag1, GEXP18) and top 4 (SL:4-covar, which included PfMSP1$_{19}$) as covariates resulted in further lowered AUC values with 0.8790 and 0.8967, respectively, and identified >50% of the *P. falciparum* cases (Supplementary Table 1).

Performing Random Forest models outside SL (using Random Forest package) had the same predictions as SL-RF, and using the 4 covariates Etramp5.Ag1, PfGLURP R2, GEXP18 and PfMSP1$_{19}$ (RF.covar4) gave an AUC of 0.9983 for the training data and 0.9591 for the test data – the highest for all Pf models tested (Figure 3C; Supplementary Table 1). The RF.covar4 model was able to accurately identify 92.8% of the *P. falciparum* infections in our data, and had a comparable AUC with the RF 8-covariate model (RF.covar8), showing that analysis using the 4 antigens is sufficient for predicting recent *P. falciparum* infection or exposure (Figure 3C; Supplementary Table 1). Meanwhile, predictions of *P. vivax* recent exposure were also not different for the SL, RF and GBM models (Figure 4D; Supplementary Table 2).

The predictive performance of the resulting SL models (SL:3-covar, SL:4-covar, SL:8-covar, SL:9-covar for Pf exposure predictions, and SL:6-covar for Pv exposure predictions) were then compared with RF (both species) and GBM (for Pv) predictions (RF.covar4 and RF.covar8 for Pf; RF.covar6 and GBM.covar6 for Pv) (Figure 4G & 4H), and the rates of predicted current *P. falciparum* infection based on SL and RF models all consistently gave 0-0.2% prediction for Occidental Mindoro and Bataan, where no *P. falciparum* malaria cases were reported in recent years, suggesting that these models can accurately predict the absence of recent falciparum malaria exposure and infection (Figure 4G). Analysis of antibody responses to *P. vivax*

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 5. Seroconversion curves based on reverse catalytic models using AMA1 and MSP1$_{19}$ antibody responses provide accurate estimates of historical exposure. Age-specific seroprevalence was based on finite mixture models and Random Forest models (using both antigens: RF 2-covar models) for each species. Solid lines represent the fit of the reversible catalytic models, dashed lines represent 95% confidence intervals, and dots represent the observed proportions of seropositives per age divided into 10% centiles. For models assuming a change point in transmission, only the recent seroconversion rates and change point estimates (in years) are shown, while the historical seroconversion rates and seroreversion rates are detailed in Table 4.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

antigens also had <1% prediction rate for Bataan and <5% for Occidental Mindoro, also indicative of the absence of recent *P. vivax* infections in these sites (Figure 4H; Supplementary Table 2).

To further evaluate the performance of the RF 4-covariate model for predicting *P. falciparum* recent exposure, external validation was performed using an available test dataset that included samples from a cross-sectional survey in Malaysia (n=8163; **Fornace et al., 2018**), PCR-validated malaria cases (Pf=47, non-Pf=423), and malaria-naïve or malaria-negative samples (n=511). The model prediction resulted in an AUC of 0.93 (CI 0.8817-0.9782), and was able to predict 0.47% prevalence of infection for the cross-sectional survey, correctly identifying 41 of 47 (87.2%) of the *P. falciparum* PCR-confirmed cases seen in the survey. The observation that this relatively simple model was able to provide accurate predictions for both the Philippine and Malaysian datasets suggests potential as a robust indicator for recent exposure and current infections, in areas with varying levels of transmission.

Estimating P. falciparum and P. vivax historical exposure

AMA1 and $MSP1_{19}$ responses for *P. falciparum* and *P. vivax* have been widely used to assess historical

Table 4. Seroconversion and seroreversion rates from reverse catalytic models in each study site

		Bataan	Occidental Mindoro	Palawan
PfAMA1	$SCR_{historical}$	0.02102 (0.00599 - 0.07375)	0.03306 (0.02150 - 0.05082)	0.06953 (0.06251 - 0.07736)
	SCR_{recent}	0.00193 (0.00112 - 0.00332)	0.01024 (0.00707 - 0.01483)	0.13346 (0.11802 - 0.15092)
	SRR	0.010002 (0.0010 - 0.10353)	0.01239 (0.00575 - 0.02673)	0.00841 (0.00626 - 0.01129)
	Time of change in transmission (yrs)	29	12	2
$PfMSP1_{19}$	$SCR_{historical}$	0.04042 (0.00836 - 0.19516)	0.03399 (0.02221 - 0.05204)	0.07521 (0.06658 - 0.08495)
	SCR_{recent}	0.00243 (0.00148 - 0.00396)	0.01412 (0.00842 - 0.02367)	0.14811 (0.13109 - 0.16734)
	SRR	0.01959 (0.00564 - 0.06796)	0.01779 (0.00926 - 0.03416)	0.01221 (0.00946 - 0.01575)
	Time of change in transmission (yrs)	33	7	2
RF with PfAMA1 and $PfMSP1_{19}$	$SCR_{historical}$	0.01513 (0.00426 - 0.05370)	0.03338 (0.02172 - 0.05130)	0.06836 (0.06133 - 0.07619)
	SCR_{recent}	0.00122 (0.00064 - 0.00234)	0.00931 (0.00630 - 0.01377)	0.12847 (0.11333 - 0.14564)
	SRR	0.00463 (0.00002 - 0.91264)	0.01327 (0.00639 - 0.02755)	0.00901 (0.00674 - 0.01204)
	Time of change in transmission (yrs)	29	12	2
PvAMA1	$SCR_{historical}$	0.07078 (0.01619 - 0.30943)	0.02760 (0.02094 - 0.03638)	0.05210 (0.04652 - 0.05834)
	SCR_{recent}	0.00197 (0.00102 - 0.00377)	0.00840 (0.00451 - 0.01564)	0.08800 (0.07591 - 0.10202)
	SRR	0.03138 (0.01524 - 0.06460)	0.00715 (0.00269 - 0.01898)	0.01074 (0.00801 - 0.01441)
	Time of change in transmission (yrs)	29	7	2
PvMSP119	$SCR_{historical}$	0.02858 (0.00465 - 0.17570)	0.01143 (0.00921 - 0.01419)	0.03760 (0.03172 - 0.04458)
	SCR_{recent}	0.00178 (0.00092 - 0.00347)		0.08687 (0.07507 - 0.10052)
	SRR	0.02941 (0.00862 - 0.10026)	0.00404 (0.00047 - 0.03486)	0.02146 (0.01599 - 0.02880)
	Time of change in transmission (yrs)	28	-	2
RF with PvAMA1 and PvMSP119	$SCR_{historical}$	0.03387 (0.00559 - 0.20521)	0.01139 (0.00919 - 0.01414)	0.04023 (0.03472 - 0.04661)
	SCR_{recent}	0.00169 (0.00084 - 0.00340)		0.08479 (0.07313 - 0.09833)
	SRR	0.03498 (0.01265 - 0.09673)	0.00388 (0.00042 - 0.03598)	0.02227 (0.01674 - 0.02963)
	Time of change in transmission (yrs)	28	-	2

Seroconversion rates (SCR) and seroreversion rates (SRR) are presented for *P. falciparum* and *P. vivax* based on reverse catalytic models using age-specific seroprevalence from finite mixture models with AMA1 and $MSP1_{19}$ and Random Forest (RF) 2-covariate models. If the best reverse catalytic model to fit the age-adjusted seropositivity data was one with no change point in transmission, only 1 SCR is indicated, while if the best fit is one with a change point, the SCR before the change point is indicated as $SCR_{historical}$ and the SCR after the change point is indicated as SCR_{recent}. The estimated change point in transmission (in years) is also indicated.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 6. Cumulative exposure markers confirm historical *P. falciparum* and *P. vivax* exposure, and heterogeneity of transmission in the 3 sites

A. Plot of Super Learner prediction values for Pf historical exposure by site and age, using the model with 8 Pf-specific serological markers as covariates. Red dotted line represents positivity cutoff at 0.5.

B. Variable importance based on the Random Forest model of the 8 Pf-specific antigens and 6 Pv-specific antigens in predicting historical exposure for each species.

C. Distribution of antibody responses to PfAMA1 by site and age of individuals (n=9132). Red dashed line represents the seropositivity cutoff value from the FMM model.

D-E. Summary graphs per age category per site of SL-predicted Pf historical exposure (D) and PfAMA1, PfMSP1 seropositivity rates graphed with estimated historical exposure rates using the Random Forest model with PfAMA1, PfMSP1$_{19}$ as covariates (E).

F. Summary graph of PvAMA1, PvMSP1 seropositivity rates with estimated historical exposure rates using the Random Forest model with PvAMA1, PvMSP1$_{19}$ as covariates seropositivity per age category per site

355

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

exposure by estimating seroconversion and seroreversion rates. Using reverse catalytic models and maximum likelihood tests on the age-specific seroprevalence based on the FMM model seropositivity rates for PfAMA1, PfMSP1$_{19}$, PvAMA1 and PvMSP1$_{19}$, we estimated the time of interruption of transmission in our study area (Figure 5, Table 4).

The Random Forest algorithm was also employed to generate models that make use of both cumulative exposure antigens (2-covariate models for the 2 species: Pf-RF:2-covar and Pv-RF:2-covar), and the predicted binary outcomes were also used in the reverse catalytic models. Most of the seroconversion curves were best fit with a model assuming a change in transmission based on log likelihood tests (p < 0.001), except for PvMSP1$_{19}$ (p= 0.507) and the RF-Pv model (p=0.285) with PvAMA1 and PvMSP1$_{19}$ as covariates (Table 4).

Based on these models, the time of change in transmission in Bataan was estimated at 29-33 years for *P. falciparum* and 28-29 years for *P. vivax*. Occidental Mindoro had varied estimates of the change point (7 and 12 years), while PvMSP1$_{19}$ and consequently the RF Pv 2-covar model did not better fit in the model assuming a change in transmission. For these 2 provinces, the seroconversion rates were decreased after the change point, suggesting a decrease in transmission, while for Palawan, an increase of the seroconversion rates was observed in all models after the 2-year change point, suggesting that there was an increase in transmission in this study site.

We further explored whether the use of the SL model can provide improved estimates of historical exposure. The 8 Pf antigens and 6 Pv antigens were separately used as covariates, and the binary classification derived from the SL prediction values for each site by age group were then compared with the single antigen seropositivity rates and RF 2-covariate models' estimated exposure rates (Figure 6A & 6C, summarized in Figure 6D & 6E, respectively). The contribution of each covariate based on the RF model (Figure 6B), as expected, showed that the antigens associated with long-lived antibody responses – AMA1 and MSP1$_{19}$ – had the highest influence in the prediction for both *P. falciparum* and *P. vivax* historical exposure. However, comparing the SL-predicted rates with seropositivity rates of the top Pf antigen PfAMA1 (Figure 6A & 6B) show that SL overestimated historical exposure, with higher-than-expected positivity rates observed in younger age groups from Bataan and Occidental Mindoro where transmission is reportedly absent (Figure 6E). The seropositivity rates based on the 2-covariate RF models with AMA1 and MSP1$_{19}$ seem to provide better estimates of historical exposure to both *P. falciparum* and *P. vivax* based on known malaria prevalence of the sites than the SL models that included all antigens (Figure 6E & 6F).

Discussion

In this study we assessed the utility of multiple antigen specific antibody responses and different statistical methods to estimate both current malaria infection and historical transmission in areas of different endemicity in the Philippines. Using a multiplex bead-based assay with a panel of 8 *P. falciparum*-specific and 6 *P. vivax*-specific recombinant antigens, we showed that whilst antibody levels to most antigens described broad differences in transmission, Random Forest predictions with 4 *P. falciparum*-specific antigens (Etramp5.Ag1, PfGLURP R2, GEXP18 and PfMSP1$_{19}$) accurately identified >90% of *P. falciparum* infections in the data. Rates of predicted infection with these models were also highly consistent with ongoing levels of transmission described by routine data. Similar observations were made for *P. vivax* with 2 antigens (PvMSP1$_{19}$ and PvAMA1) but with lower precision. Moreover, reconstruction of historical transmission patterns was improved by combining seropositivity to two antigens (MSP1$_{19}$ and AMA1 for both *P. falciparum* and *P. vivax*) assessed using finite mixture models, and further improved using the Random Forest model on continuous data from these antigens combined. These findings highlight the potential for advanced

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

analysis of multiplex serological data to provide additional accurate data on incidence levels that could be used by control programs at small spatial scales.

The use of multiple antigens to assess exposure to malaria infection circumvents some issues related to genetic diversity in the parasite and variation in the human immune response to different antigenic targets. The approach also allows application of more advanced statistical analysis to examine optimal combinations of antibody responses in predicting specific outcomes. Here, in addition to the well-studied antigens AMA1 and $MSP1_{19}$, we screened other antigenic markers that have been reported to accurately predict recent exposure in studies in Africa and the Caribbean **(Helb et al., 2015; van den Hoogen et al., 2020c; Wu et al., 2020a)**. We then employed a machine learning approach for predicting classification outcomes of disease exposure which has been used previously to analyze antibody response data **(Helb et al., 2015; Longley et al., 2020; Rosado et al., 2020)**. We showed that the machine learning models were able to both confirm the absence of current infection in Occidental Mindoro and Bataan, and, using the Random Forest predictions from a 4-covariate model including PfGLURP R2, Etramp5.Ag1, GEXP18 and $PfMSP1_{19}$, accurately identify >92% of the *Plasmodium*-positive study samples from this study, whether detected through microscopy, RDT and/or PCR. The relative simplicity of this model and lack of requirement for basic epidemiological variables such as age is a benefit in assessing current infection and recent exposure, including stable transmission settings (*i.e.,* like in Palawan with an API of >5 for the whole province, and >30 for the study site Rizal). We expected that the Super Learner model would improve the predictions with its ensemble approach; however, for predicting *P. falciparum* current infections in particular, RF-based models had the better AUC for both training and test data. This was not the case for the *P. vivax* current infection predictions, which showed similar AUCs (<0.7) for the final SL model and its component models. RF variable importance showed that $PvMSP1_{19}$ was the most predictive among the 6 antigens in our panel, which is consistent with the recent study by Longley et al (2020), likewise utilizing a RF prediction algorithm that identified $PvMSP1_{19}$ as one of the 8 most predictive *P. vivax* recent exposure markers. It is likely that the low AUC and predictive ability we observed is a limitation of the panel of antigens available to us at the time of the study rather than the analytical approach itself. Notwithstanding, the SL approach was able to provide the means for evaluating multiple supervised machine learning models simultaneously, and, for the purpose of accurately distinguishing recent exposure from historical exposure with high sensitivity, the RF model seems to be the most predictive. The satisfactory results from the external validation using the cross-sectional survey data from Malaysia also suggests broader utility not least in neighboring Southeast Asian countries with similar historical transmission patterns.

In stratification of malaria transmission, a key component is determining its absence. In many countries including the Philippines, malaria-endemic provinces apply for malaria-free status when indigenous or local cases have not been reported for a set number of years, typically 3 or more. More rapid, subnational demonstration of the absence of exposure could aid in this process. Cumulative exposure markers are used in various studies to estimate malaria transmission intensities, wherein age-specific seroprevalence can be used to confirm the level of historical exposure of endemic areas. Malaria-specific serological assays can then be utilized for determining the absence of transmission by evaluating antibody responses of populations. In assessing the individual performances of recent exposure markers, it can be observed that younger age groups in Bataan reported <10% seropositivity, although this province has not reported indigenous cases since 2011, and this may be attributed to background seropositivity. Moreover, the lower seropositivity rates observed in younger age groups in Palawan may be attributed to children who have not yet developed adequate IgG responses for detection in a serological assay. Nevertheless, our results provide an alternative approach using a multiplex analysis of 4 predictive *P. falciparum* serological markers that was able to improve the computation of binary outcomes for accurately predicting current or recent falciparum malaria infections.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Strong correlations among the *P. falciparum* and *P. vivax* antigens in the panel were observed, consistent with previous observations **(Chotirat et al., 2021; Rogier et al., 2021)** and suggesting the combined risk of *P. falciparum* and *P. vivax* infection in Rizal, Palawan. Nonetheless, our results also indicate that the *P. falciparum*-positive and *P. vivax*-positive samples had species-specific increase and significantly different patterns in its antibody responses to the *P. falciparum* and *P. vivax*-specific antigens. The simultaneous cumulative increase in species-specific antibodies has been explored for its possible role in the development of cross-protective immunity **(Gnidehou et al., 2019; Mitran and Yanow, 2020; Muh et al., 2020)**, and can be an area for further investigation, as this could potentially explain the observed asymptomatic PCR-only cases (including mixed infections) in Rizal, Palawan **(Reyes et al., 2021)**.

This study had a number of limitations. Since the study analyzed samples from a health facility-based survey, whether or not it accurately represents the populations needs to be assessed. Due to the nature of the survey we were only able to sample health-seeking individuals, though this was partially addressed by also recruiting companions of patients who visited the health facilities **(Reyes et al., 2021)**. For predicting recent infections, we had not asked survey participants if they recently had malaria, or if they had past malaria episodes for that matter (self-reported malaria history), such that we have only attempted to predict current infections. Still, external validation of our prediction algorithm for *P. falciparum* infection confirms its promising performance in accurately predicting malaria infections.

There are also no accessible detailed records of the malaria history of individual visitors in the health facilities, such that the results for the predicted historical exposure cannot be validated. Nonetheless, we are able to show that consistent with previous studies **(Biggs et al., 2017; Idris et al., 2017; Perraut et al., 2014; Rosas-Aguirre et al., 2015; Wu et al., 2020b)**, seropositivity rates from cumulative exposure markers AMA1 and $MSP1_{19}$ for *P. falciparum* and *P. vivax* seemed to agree with the known malaria situation of our study sites. The "historical positives" used as training data for predicting historical exposure were the adult population (aged 50 years old and above) in malaria-endemic areas, wherein we assumed that all these individuals were exposed at some point, and that their antibody profiles would reflect historical exposure. The high variations in the dataset would have greatly affected these predictions. Since the reference population data available for predicting historical exposure using supervised classification approaches was not suitable, using the unsupervised approach of determining AMA1 and $MSP1_{19}$ seropositivity rates based on FMM may then suffice. Based on the known malaria situation in the collection sites, results from the SL model, RF 2-covar model and individual seropositivity rates of AMA1 and $MSP1_{19}$ may be able to provide a reliable estimate of malaria exposure in the area. The seroconversion rates also reflect the transmission status of our sites, with Bataan having the lowest, followed by Occidental Mindoro, and highest for Palawan. Our results are able to confirm the absence of *P. falciparum* and *P. vivax* transmission in malaria-free Bataan for the age groups 10 and below, providing evidence for its malaria elimination status. Moreover, the change point in transmission for Bataan is estimated higher but still consistent with the results of a serological survey conducted in the same area a year prior, which estimated the change point at 22 years **(van den Hoogen et al., 2020a)**, and coincided with the decline in cases in the municipality. For Occidental Mindoro, the interruption in transmission from 7-12 years ago may be explained by the extensive malaria control activities implemented in the area, as the province has been part of the priority provinces of the Global Fund for Malaria since the 2000s. Our seroconversion curve results also suggest an increase in malaria transmission in Rizal, Palawan during the time of our survey (2016 to 2018), and upon checking the numbers of the reported malaria cases, there was indeed a steady rise of the API in this municipality from 25.43 in 2014, 33.97 in 2015, to 46.09 in 2016 and 56.78 in 2018.

The longevity of IgG antibody responses to malaria-specific antigens has the potential to also provide information on the development of naturally acquired immunity in populations **(King et al., 2015)** – although if and how assay responses translate to immune protection is not well understood **(Crompton et al., 2010;**

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Proietti et al., 2019; Stanisic et al., 2015). From the 3 sites in the study, we were able to detect *Plasmodium* infections only in Rizal, Palawan. Asymptomatic infections comprised 265 (44.5%) of the malaria cases detected, and were observed in all age groups, which suggests the development of clinical immunity in this endemic population with relatively stable transmission. Our results showed that >80% of the PfAMA1 seropositives in Bataan had lived there for >10 years, and had net MFI levels that were comparable with adults in Occidental Mindoro and Palawan (data not shown), suggesting that what we observed could be long-lived antibody responses to *P. falciparum* and *P. vivax* malaria in the population. Still, the lower seropositivity rates in Bataan and Occidental Mindoro, areas which had high transmission 20 and <10 years ago, respectively, may highlight the impact of a reduced transmission in malaria immune responses. Still, our data supports the notion that long-lived antibodies can be maintained even in the absence of ongoing transmission. Of interest for countries aiming for elimination is evaluating the impact of a decrease in transmission on the immunity or vulnerability of a population, especially in differing endemic settings **(Fowkes et al., 2016; World Health Organization, 2017)**. Understanding the generation and maintenance of effective immune responses during natural infection, particularly in the era of changing malaria epidemiology, is crucial for the rational development and evaluation of future interventions and vaccines. Immunological studies are needed to investigate this further.

Despite the mentioned limitations of the study, our results clearly show the potential use of multiplex antibody responses and applications of machine learning approaches in assessing malaria transmission for countries aiming for malaria elimination. In a sub-national elimination setting such as the Philippines, both recent and historical *P. falciparum* and *P. vivax* exposure metrics were indicative of the absence of recent transmission in Bataan and Occidental Mindoro, and were also able to identify current infections in Rizal, Palawan, thus showing its ability in assessing the malaria situation in varying areas of endemicity. These serological markers provide accurate estimates of recent and historical exposure to malaria and our study provides baseline immunological data for monitoring risk populations. This serological surveillance approach can aid in devising control measures by malaria elimination programs, as well as provide evidence of the effectiveness of programs being implemented.

Acknowledgements

This study was supported by the Newton Fund, Philippine Council for Health Research and Development, and UK Medical Research Council through funding received for ENSURE: Enhanced surveillance for control and elimination of malaria in the Philippines (MR/N019199/1). We also express our gratitude to the ENSURE team, specially Carol Joy Sarsadiaz, Hennessey Sabanal, Beaulah Boncayao and Ellaine de la Fuente who assisted in the conduct of serological assays for this project, as well as Dr. Mario Jiz, Dr. Catalino Demetria, and Dr. Marilou Nicolas who provided technical assistance and access to their Luminex 200 instruments. Also, we thank the local government and health staff of Palawan, Occidental Mindoro and Bataan for their invaluable support to our research. This work is also supported by the Nagasaki University "Doctoral Program for World-leading Innovative and Smart Education" for Global Health, "Global Health Elite Programme for Building a Healthier World".

Author Contributions

CJD, FEJE, JCRH, and MLMM conceived and designed this study. MLMM, KMF and CJD analyzed and interpreted the data. MLMM wrote the first draft of the manuscript with support from KMF, CJD, JCRH, KY, and FEJE. JSL, RAR, MLMM, and APNB supervised the data and sample collection, and the conduct of assays. KKAT, JHA, CH, and CEC provided the recombinant antigens used for the multiplex bead-based assay. MLMM and RAR performed the serological assays with support from TH and KKAT. All authors read and approved the final manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Competing interests

The authors declare no competing interests.

References

Biggs J, Raman J, Cook J, Hlongwana K, Drakeley C, Morris N, et al. Serology reveals heterogeneity of Plasmodium falciparum transmission in northeastern South Africa: Implications for malaria elimination. *Malar J* 2017;16. https://doi.org/10.1186/s12936-017-1701-7.

Burghaus PA, Holder AA. Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. *Mol Biochem Parasitol* 1994;64:165–9. https://doi.org/10.1016/0166-6851(94)90144-9.

Chotirat S, Nekkab N, Kumpitak C, Hietanen J, White MT, Kiattibutr K, et al. Application of 23 novel serological markers for identifying recent exposure to Plasmodium vivax parasites in an endemic population of western Thailand. *MedRxiv* 2021:2021.03.01.21252492.

Chuquiyauri R, Molina DM, Moss EL, Wang R, Gardner MJ, Brouwer KC, et al. Genome-scale protein microarray comparison of human antibody responses in plasmodium vivax relapse and reinfection. *Am J Trop Med Hyg* 2015;93:801–9. https://doi.org/10.4269/ajtmh.15-0232.

Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH, Thomas AW, Blackman MJ. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. *J Biol Chem* 2007;282:7431–41. https://doi.org/10.1074/jbc.M610562200.

Corran P, Coleman P, Riley E, Drakeley C. Serology: a robust indicator of malaria transmission intensity? *Trends Parasitol* 2007;23:575–82. https://doi.org/10.1016/j.pt.2007.08.023.

Coutts SP, King JD, Pa'au M, Fuimaono S, Roth J, King MR, et al. Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration. *Trop Med Health* 2017;45:1–10. https://doi.org/10.1186/s41182-017-0063-8.

Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. *Proc Natl Acad Sci U S A* 2010;107:6958–63. https://doi.org/10.1073/pnas.1001323107.

Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, Carneiro I, et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. *Proc Natl Acad Sci* 2005;102:5108–13. https://doi.org/10.1073/pnas.0408725102.

Folegatti PM, Siqueira AM, Monteiro WM, Lacerda MVG, Drakeley CJ, Braga ÉM. A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection. *Malar J* 2017;16:107. https://doi.org/10.1186/s12936-017-1762-7.

Fornace KM, Brock PM, Abidin TR, Grignard L, Herman LS, Chua TH, et al. Environmental risk factors and exposure to the zoonotic malaria parasite Plasmodium knowlesi across northern Sabah, Malaysia: a population-based cross-sectional survey. *Lancet Planet Heal* 2019;3:e179–86. https://doi.org/10.1016/S2542-5196(19)30045-2.

Fornace KM, Herman LS, Abidin TR, Chua TH, Daim S, Lorenzo PJ, et al. Exposure and infection to Plasmodium knowlesi in case study communities in Northern Sabah, Malaysia and Palawan, The Philippines. *PLoS Negl Trop Dis* 2018;12:e0006432. https://doi.org/10.1371/journal.pntd.0006432.

Fouda GG, Leke RFG, Long C, Druilhe P, Zhou A, Taylor DW, et al. Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. *Clin Vaccine Immunol* 2006;13:1307–13. https://doi.org/10.1128/CVI.00183-06.

Fowkes FJI, Boeuf P, Beeson JG. Immunity to malaria in an era of declining malaria transmission. *Parasitology* 2016;143:139–53. https://doi.org/10.1017/S0031182015001249.

Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. *PLoS Med* 2010;7. https://doi.org/10.1371/journal.pmed.1000218.

França CT, He WQ, Gruszczyk J, Lim NTY, Lin E, Kiniboro B, et al. Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children. *PLoS Negl Trop Dis* 2016a;10:1–17. https://doi.org/10.1371/journal.pntd.0005014.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

França CT, Hostetler JB, Sharma S, White MT, Lin E, Kiniboro B, et al. An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection. *PLoS Negl Trop Dis* 2016b;10:1–15. https://doi.org/10.1371/journal.pntd.0004639.

Gnidehou S, Mitran CJ, Arango E, Banman S, Mena A, Medawar E, et al. Cross-species immune recognition between plasmodium vivax duffy binding protein antibodies and the plasmodium falciparum surface antigen VAR2CSA. *J Infect Dis* 2019;219:110–20. https://doi.org/10.1093/infdis/jiy467.

Helb DA, Tetteh KKA, Felgner PL, Skinner J, Hubbard A, Arinaitwe E, et al. Novel serologic biomarkers provide accurate estimates of recent *Plasmodium falciparum* exposure for individuals and communities. *Proc Natl Acad Sci* 2015;112:E4438–47. https://doi.org/10.1073/pnas.1501705112.

Hester J, Chan ER, Menard D, Mercereau-Puijalon O, Barnwell J, Zimmerman PA, et al. De Novo Assembly of a Field Isolate Genome Reveals Novel Plasmodium vivax Erythrocyte Invasion Genes. *PLoS Negl Trop Dis* 2013;7. https://doi.org/10.1371/journal.pntd.0002569.

van den Hoogen LL, Bareng P, Alves J, Reyes R, Macalinao M, Rodrigues JM, et al. Comparison of Commercial ELISA Kits to Confirm the Absence of Transmission in Malaria Elimination Settings. *Front Public Heal* 2020a;8:1–12. https://doi.org/10.3389/fpubh.2020.00480.

van den Hoogen LL, Griffin JT, Cook J, Sepúlveda N, Corran P, Conway DJ, et al. Serology describes a profile of declining malaria transmission in Farafenni, The Gambia. *Malar J* 2015;14:416. https://doi.org/10.1186/s12936-015-0939-1.

van den Hoogen LL, Présumé J, Romilus I, Mondélus G, Elismé T, Sepúlveda N, et al. Quality control of multiplex antibody detection in samples from large-scale surveys: the example of malaria in Haiti. *Sci Rep* 2020b;10:1–10. https://doi.org/10.1038/s41598-020-57876-0.

van den Hoogen LL, Stresman G, Présumé J, Romilus I, Mondélus G, Elismé T, et al. Selection of Antibody Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination. *Front Immunol* 2020c;11:1–12. https://doi.org/10.3389/fimmu.2020.00928.

van den Hoogen LL, Walk J, Oulton T, Reuling IJ, Reiling L, Beeson JG, et al. Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium falciparum Infections. *Front Microbiol* 2019;9:1–11. https://doi.org/10.3389/fmicb.2018.03300.

Hubbard A, Munoz ID, Decker A, Holcomb JB, Schreiber MA, Bulger EM, et al. Time-dependent prediction and evaluation of variable importance using superlearning in high-dimensional clinical data. *J Trauma Acute Care Surg* 2013;75:1–12. https://doi.org/10.1097/TA.0b013e3182914553.

Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, et al. Serological measures to assess the efficacy of malaria control programme on Ambae Island, Vanuatu. *Parasites and Vectors* 2017;10. https://doi.org/10.1186/s13071-017-2139-z.

Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, et al. Serological markers to measure recent changes in malaria at population level in Cambodia. *Malar J* 2016;15:1–18. https://doi.org/10.1186/s12936-016-1576-z.

King CL, Davies DH, Felgner P, Baum E, Jain A, Randall A, et al. Biosignatures of Exposure/Transmission and Immunity. *Am J Trop Med Hyg* 2015;93:16–27. https://doi.org/10.4269/ajtmh.15-0037.

Koffi D, Touré AO, Varela ML, Vigan-Womas I, Béourou S, Brou S, et al. Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX™). *Malar J* 2015;14. https://doi.org/10.1186/s12936-015-1043-2.

Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, et al. Development and validation of serological markers for detecting recent Plasmodium vivax infection. *Nat Med* 2020;26:741–9. https://doi.org/10.1038/s41591-020-0841-4.

malERA Refresh Consultative Panel. malERA: An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication. *PLOS Med* 2017;14:e1002452. https://doi.org/10.1371/journal.pmed.1002452.

Menard D, Chan ER, Benedet C, Ratsimbasoa A, Kim S, Chim P, et al. Whole Genome Sequencing of Field Isolates Reveals a Common Duplication of the Duffy Binding Protein Gene in Malagasy Plasmodium vivax Strains. *PLoS Negl Trop Dis* 2013;7. https://doi.org/10.1371/journal.pntd.0002489.

Mitran CJ, Yanow SK. The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design. *Front Immunol* 2020;11:1–14. https://doi.org/10.3389/fimmu.2020.00335.

Muh F, Kim N, Nyunt MH, Firdaus ER, Han JH, Hoque MR, et al. Cross-species reactivity of antibodies against

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

plasmodium vivax blood-stage antigens to plasmodium knowlesi. *PLoS Negl Trop Dis* 2020;14:1–21. https://doi.org/10.1371/journal.pntd.0008323.

Niass O, Saint-Pierre P, Niang M, Diop F, Diouf B, Faye MM, et al. Modelling dynamic change of malaria transmission in holoendemic setting (Dielmo, Senegal) using longitudinal measures of antibody prevalence to Plasmodium falciparum crude schizonts extract. *Malar J* 2017;16:1–12. https://doi.org/10.1186/s12936-017-2052-0.

Ntumngia FB, Schloegel J, Barnes SJ, Mchenry AM, Singh S, King CL, et al. Conserved and variant epitopes of Plasmodium vivax duffy binding protein as targets of inhibitory monoclonal antibodies. *Infect Immun* 2012;80:1203–8. https://doi.org/10.1128/IAI.05924-11.

Ondigo BN, Park GS, Gose SO, Ho BM, Ochola LA, Ayodo GO, et al. Standardization and validation of a cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigens. *Malar J* 2012;11:1–17. https://doi.org/10.1186/1475-2875-11-427.

Perraut R, Richard V, Varela ML, Trape JF, Guillotte M, Tall A, et al. Comparative analysis of IgG responses to Plasmodium falciparum MSP1p19 and PF13-DBL1α1 using ELISA and a magnetic bead-based duplex assay (MAGPIX®-Luminex) in a Senegalese meso-endemic community. *Malar J* 2014;13. https://doi.org/10.1186/1475-2875-13-410.

Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. *Vaccine* 2006;24:4233–46. https://doi.org/10.1016/j.vaccine.2005.06.030.

Pothin E, Ferguson NM, Drakeley CJ, Ghani AC. Estimating malaria transmission intensity from Plasmodium falciparum serological data using antibody density models. *Malar J* 2016;15:79. https://doi.org/10.1186/s12936-016-1121-0.

Proietti C, Krause L, Trieu A, Dodoo D, Gyan B, Koram KA, et al. Immune signature against Plasmodium falciparum antigens predicts clinical immunity in distinct malaria endemic communities. *Mol Cell Proteomics* 2019:mcp.RA118.001256. https://doi.org/10.1074/mcp.RA118.001256.

Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S, et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. *Science (80-)* 2014;344:871–7. https://doi.org/10.1126/science.1254417.

Reyes RA, Fornace KM, Macalinao MLM, Boncayao BL, de la Fuente ES, Sabanal HM, et al. Enhanced health facility surveys to support malaria control and elimination across different transmission settings in the Philippines. *Am J Trop Med Hyg* 2021;104:968–78. https://doi.org/10.4269/ajtmh.20-0814.

Rogier E, Nace D, Dimbu PR, Wakeman B, Pohl J, Beeson JG, et al. Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection. *Front Immunol* 2021;12:1–11. https://doi.org/10.3389/fimmu.2021.617951.

Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. *The Lancet Microbe* 2020;5247:1–10. https://doi.org/10.1016/s2666-5247(20)30197-x.

Rosas-Aguirre A, Speybroeck N, Llanos-Cuentas A, Rosanas-Urgell A, Carrasco-Escobar G, Rodriguez H, et al. Hotspots of malaria transmission in the Peruvian amazon: Rapid assessment through a parasitological and serological survey. *PLoS One* 2015;10. https://doi.org/10.1371/journal.pone.0137458.

Sepúlveda N, Stresman G, White MT, Drakeley CJ. Current mathematical models for analyzing anti-malarial antibody data with an eye to malaria elimination and eradication. *J Immunol Res* 2015;2015. https://doi.org/10.1155/2015/738030.

Spielmann T, Fergusen DJP, Beck H-P. etramps , a New Plasmodium falciparum Gene Family Coding for Developmentally Regulated and Highly Charged Membrane Proteins Located at the Parasite–Host Cell Interface. *Mol Biol Cell* 2003;14:1529–44. https://doi.org/10.1091/mbc.e02-04-0240.

Ssewanyana I, Arinaitwe E, Nankabirwa JI, Yeka A, Sullivan R, Kamya MR, et al. Avidity of anti - malarial antibodies inversely related to transmission intensity at three sites in Uganda. *Malar J* 2017:1–8. https://doi.org/10.1186/s12936-017-1721-3.

Stanisic DI, Fowkes FJI, Koinari M, Javati S, Lin E, Kiniboro B, et al. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. *Infect Immun* 2015;83. https://doi.org/10.1128/IAI.02398-14.

Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. *Infect Immun* 1995;63:4382–8. https://doi.org/10.1128/iai.63.11.4382-4388.1995.

Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. *Clin Diagn Lab Immunol* 1995;2:30–4. https://doi.org/10.1128/cdli.2.1.30-34.1995.

World Health Organization. World Malaria Report 2019. vol. WHO/HTM/GM. Geneva, Switzerland: 2019.

World Health Organization. WHO malaria policy advisory committee meeting: meeting report, October 2017. Geneva, Switzerland: 2017.

World Health Organization. Progress towards subnational elimination in the Philippines. Geneva PP - Geneva: World Health Organization; 2014.

World Health Organization, Global Malaria Programme. A Framework for Malaria Elimination. 2017. https://doi.org/Licence: CC BY-NC-SA 3.0 IGO.

Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, Vasileva H, et al. Optimisation and standardisation of a multiplex immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria transmission using sero-epidemiology. *Wellcome Open Res* 2019;4:26. https://doi.org/10.12688/wellcomeopenres.14950.1.

Wu L, Mwesigwa J, Affara M, Bah M, Correa S, Hall T, et al. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration. *BMC Med* 2020a;18:1–14. https://doi.org/10.1186/s12916-020-01785-6.

Wu L, Mwesigwa J, Affara M, Bah M, Correa S, Hall T, et al. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia. *BMC Med* 2020b:2020.07.10.20067488. https://doi.org/10.1101/2020.07.10.20067488.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary Figure 1. Antibody levels in response to the rest of the *P. falciparum* and *P. vivax* serological markers in the panel, by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons.
Related to Fig. 1.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

716



Supplementary Figure 2. Antibody responses of malaria-negative and malaria-positive populations (presented as density plots of log10 net MFI values) to the Pf and Pv serological markers in the panel (Pf and Pv diagnosed by microscopy, RDT and/or PCR.
Related to Fig. 1.

717

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary Figure 3. Performances of the individual base learners in the Super Learner ensemble.

A-B) Plots of the assigned weights to each learner included in the Super Learner models for predicting *P. falciparum* (A) and *P. vivax* recent exposure (B), obtained after 20-fold nested cross-validation of the Pf SL-covar8 and Pv SL-covar6 models.

C-D) Receiver operating characteristic (ROC) curves for detecting current Pf (C) and Pv (D) infections in the test dataset (n=9132) using the 8 Pf and 6 Pv antigens as covariates, respectively. (SL.final: final Super Learner model, RF: random Forest, RF.ranger: RF from ranger package, kNN: k-Nearest Neighbor, GBM: generalized boosted models (implementation for BRT: boosted regression trees), SVM:Support Vector Machine, and GLM: Generalized linear models; variation of algorithms with "corP" denotes a feature selection that screens for univariate correlation)

718

Supplementary Table 1. Seropositivity rates based on Pf-specific antigens and SuperLearner predictions for recent Pf exposure

Model		Seropositivity cutoff value for antigens	AUC – validation data	AUC – study data	Positive in Pf+ samples (n=625)		Positive in Palawan, n=6572 (%)		Positive in Occidental Mindoro, n=1683 (%)		Positive in Bataan, n=877 (%)	
PfAMA1	FMM	129.552007	0.9075 (0.8866-0.9284)	0.6921 (0.6771-0.7072)	509	(85.5%)	3842	(58.5%)	599	(35.6%)	91	(10.4%)
	Negpop	146.705091	0.9115 (0.892-0.9311)	0.6948 (0.6795-0.71)	507	(85.2%)	3792	(57.7%)	582	(34.6%)	82	(9.4%)
$PfMSP1_{19}$	FMM	315.978321	0.9321 (0.9182-0.9459)	0.6849 (0.6696-0.7002)	503	(84.5%)	3872	(58.9%)	639	(38.0%)	85	(9.7%)
	Negpop	294.522036	0.9301 (0.9152-0.9449)	0.6821 (0.667-0.6973)	508	(85.4%)	3940	(60.0%)	658	(39.1%)	89	(10.1%)
Etramp5.Ag1	FMM	343.006451	0.9075 (0.8918-0.9232)	0.7556 (0.7389-0.7722)	477	(80.2%)	2659	(40.5%)	267	(15.9%)	60	(6.8%)
	Negpop	254.493948	0.9111 (0.8941-0.9281)	0.7397 (0.7235-0.7559)	489	(82.2%)	2963	(45.1%)	362	(21.5%)	87	(9.9%)
GEXP18	FMM	402.149776	0.8848 (0.8663-0.9033)	0.7456 (0.7278-0.7633)	452	(76.0%)	2524	(38.4%)	203	(12.1%)	65	(7.4%)
	Negpop	267.001733	0.9037 (0.8849-0.9225)	0.7317 (0.7154-0.748)	487	(81.8%)	3067	(46.7%)	326	(19.4%)	126	(14.4%)
PfGLURP R2	FMM	346.692889	0.9206 (0.901-0.9401)	0.6849 (0.6701-0.6997)	516	(86.7%)	3817	(58.1%)	747	(44.4%)	147	(16.8%)
	Negpop	361.031502	0.9254 (0.9074-0.9435)	0.6855 (0.6706-0.7004)	512	(86.1%)	3810	(58.0%)	738	(43.9%)	143	(16.3%)
MSP2 CH150/9	FMM	137.354929	0.8558 (0.8325-0.879)	0.6849 (0.6665-0.7034)	437	(73.4%)	3093	(47.1%)	414	(24.6%)	76	(8.7%)
	Negpop	141.708302	0.8541 (0.8307-0.8774)	0.4971 (0.4921-0.5022)	437	(73.4%)	3074	(46.8%)	406	(24.1%)	75	(8.6%)
MSP2 Dd2	FMM	121.316261	0.9177 (0.9027-0.9326)	0.6762 (0.6598-0.6926)	484	(81.3%)	3673	(55.9%)	657	(39.0%)	126	(14.4%)
	Negpop	110.971531	0.9202 (0.9054-0.935)	0.6798 (0.6632-0.6965)	482	(81.0%)	3607	(54.9%)	615	(36.5%)	105	(12.0%)
PfSEA	FMM	733.501223	0.8207 (0.7975-0.844)	0.6714 (0.6515-0.6912)	384	(64.5%)	2387	(36.3%)	470	(27.9%)	131	(14.9%)
	Negpop	867.158828	0.8121 (0.7918-0.8324)	0.6614 (0.6411-0.6816)	357	(60.0%)	2203	(33.5%)	409	(24.3%)	112	(12.8%)
Random Forest: 4 covariates (RF.covar4)		(Etramp5.Ag1, GEXP18, PfGLURP R2, $PfMSP1_{19}$)	0.9983 (0.996-1)	0.9591 (0.9497-0.9684)	552	(92.8%)	1081	(16.4%)	5	(0.3%)	1	(0.1%)
Random Forest: 8 covariates (RF.covar8)		All 8 Pf-specific antigens	0.9898 (0.998-1)	0.9682 (0.9605-0.9759)	555	(93.3%)	1065	(16.2%)	3	(0.2%)	0	(0.0%)
SL: 3 covariates (SL:3-covar)		(Etramp5.Ag1, GEXP18, PfGLURP R2)	0.918 (0.9067-0.9293)	0.879 (0.8658-0.8921)	265	(44.5%)	809	(12.3%)	0	(0.0%)	0	(0.0%)
SL: 4 covariates (SL:4-covar)		(Etramp5.Ag1, GEXP18, PfGLURP R2, $PfMSP1_{19}$)	0.9338 (0.9214-0.9462)	0.8967 (0.8867-0.9067)	297	(49.9%)	687	(10.5%)	0	(0.0%)	0	(0.0%)
SL: 8 covariates (SL:8-covar)		All 8 Pf-specific antigens	0.955 (0.9486-0.9614)	0.914 (0.9055-0.9226)	317	(53.3%)	828	(12.6%)	0	(0.0%)	0	(0.0%)
SL: 9 covariates (SL:9-covar)		All 8 Pf-specific antigens and age	0.9898 (0.9874-0.9921)	0.9197 (0.9093-0.9302)	423	(71.1%)	1245	(18.9%)	4	(0.2%)	0	(0.0%)

*Abbreviations used: Pf: *P. falciparum;* FMM: Finite mixture model; Negpop: Negative population model; SL: Super Learner prediction model using different sets of covariates (including the 8 Pf antigens) for predicting recent and historical malaria exposure.

719

Supplementary Table 2. Seropositivity rates based on 6 Pv-specific antigens and SuperLearner predictions for recent Pv exposure

Model		Seropositivity cutoff value for antigens	AUC – validation data	AUC – study data	Positive in Pv+ samples (n=172)		Positive in Palawan, n=6572 (%)		Positive in Occidental Mindoro, n=1683 (%)		Positive in Bataan, n=877 (%)	
PvAMA1	FMM	149.776739	0.9185 (0.8934 - 0.9436)	0.6744 (0.6424 - 0.7064)	130	(75.6%)	2991	(45.5%)	650	(38.6%)	84	(9.6%)
	Negpop	172.486298	0.9164 (0.8895 - 0.9434)	0.6720 (0.6391 - 0.7049)	127	(73.8%)	3035	(46.2%)	626	(37.2%)	77	(8.8%)
$PvMSP1_{19}$	FMM	395.678911	0.9429 (0.9229 - 0.9629)	0.7308 (0.6997 - 0.7618)	134	(77.9%)	2588	(39.4%)	430	(25.5%)	63	(7.2%)
	Negpop	666.248684	0.9234 (0.8935 - 0.9533)	0.7049 (0.6692 - 0.7406)	114	(66.3%)	2135	(32.5%)	295	(17.5%)	38	(4.3%)
PvDBP.RII	FMM	403.658933	0.8036 (0.7546 - 0.8527)	0.7065 (0.6697 - 0.7434)	105	(61.0%)	1699	(25.9%)	165	(9.8%)	50	(5.7%)
	Negpop	285.09444	0.8143 (0.7668 - 0.8618)	0.7037 (0.6681 - 0.7392)	115	(66.9%)	2087	(31.8%)	221	(13.1%)	72	(8.2%)
PvRBP.1a	FMM	777.354467	0.7367 (0.6865 - 0.7869)	0.6248 (0.5871 - 0.6625)	92	(53.5%)	1979	(30.1%)	416	(24.7%)	242	(27.6%)
	Negpop	2986.35245	0.5343 (0.5006 - 0.5679)	0.5127 (0.4901 - 0.5352)	17	(9.9%)	507	(7.7%)	104	(6.2%)	61	(7.0%)
PvRII	FMM	843.409764	0.7706 (0.7195 - 0.8218)	0.6302 (0.5935 - 0.6670)	67	(39.0%)	1079	(16.4%)	104	(6.2%)	38	(4.3%)
	Negpop	377.466964	0.8007 (0.7530 - 0.8484)	0.6322 (0.5955 - 0.6688)	107	(62.2%)	2717	(41.3%)	489	(29.1%)	102	(11.6%)
PvEBP	FMM	147.668259	0.7735 (0.7247 - 0.8224)	0.6471 (0.6144 - 0.6799)	128	(74.4%)	3328	(50.6%)	719	(42.7%)	106	(12.1%)
	Negpop	661.785062	0.7133 (0.6616 - 0.7649)	0.6184 (0.5809 - 0.6559)	101	(58.7%)	2608	(39.7%)	566	(33.6%)	63	(7.2%)
SL: 6 Pv antigens		All Pv-specific antigens as covariates	0.8857 (0.8429-0.9284)	0.6332 (0.5979-0.6686)	57	(33.1%)	603	(9.2%)	35	(2.1%)	2	(0.2%)
RF: 6 Pv antigens			1	0.6918 (0.6542-0.7293)	81	(47.1%)	802	(12.2%)	57	(3.4%)	5	(0.6%)
GBM: 6 Pv antigens			0.9043 (0.8647-0.9439)	0.6462 (0.6095-0.6828)	67	(39.0%)	851	(12.9%)	80	(4.8%)	7	(0.8%)

*Abbreviations used: Pv: *P. vivax;* FMM: Finite mixture model; Negpop: Negative population model; SL: Superlearner prediction model using different sets of covariates (including the 8 Pf antigens) for predicting recent and historical malaria exposure.

720

721

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Tables and figures

Tables

Table 1. List of antigens in the multiplex bead-based assay panel

Table 2. Training and validation data used in the classification models

Table 3. Characteristics of study population by site

Table 4. Seroconversion and seroreversion rates from reverse catalytic models in each study site

Supplementary Table 1. Seropositivity rates based on Pf-specific antigens and SuperLearner predictions for recent Pf exposure

Supplementary Table 2. Seropositivity rates based on 6 Pv-specific antigens and SuperLearner predictions for recent Pv exposure

Figures

Figure 1. Map showing the study sites, with red areas as the focused municipalities within the provinces marked yellow.

Figure 2. Antibody responses to serological markers of *P. falciparum* and *P. vivax* correlate with malaria incidence

A. Antibody levels (reported as log10 MFI) in response to *P. falciparum* cumulative and recent exposure markers PfAMA1, PfMSP1$_{19}$, and Etramp5.Ag1, and *P. vivax* serological markers PvAMA1, PvMSP1$_{19}$ and PvDBP.RII by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

B. Spearman's correlation coefficients for age, malaria diagnosis (Mal+: Plasmodium-positive, Pf+: *P. falciparum*-positive, Pv+: *P. vivax*-positive), and antibody responses to the 14 antigens in the panel for Palawan samples (n=6572).

Figure 3. Serological markers exhibit species-specific association with current infection in varying levels

A-B) Comparison of antibody titers of Palawan samples (n=6572) for *Plasmodium*-positive (Pf: P. falciparum-positive, Pf/Pv: Pf and Pv mixed infection, Pv: P. vivax-positive) and negative (neg) samples by age group in each *P. falciparum*-specific (A) and *P.vivax*-specific antigen.

Figure 4. Analysis of serological markers through machine learning methods improves classifications for recent *P. falciparum* and *P. vivax* exposure or current infection

A-B. Seropositivity rates of sample population by site and age group based on cutoff values from finite mixture models (FMM) and negative population model (NegPop) for Pf and Pv antigens (detailed in **Supplementary Tables 1 and 2**). Hollow dots represent the FMM and Negpop seropositivity rates for the two reported recent exposure markers Etramp5.Ag1 and GEXP18 for Pf (A), and PvMSP1$_{19}$ and PvDBP.RII for Pv (B) panel. Lines with error bars represent median with 95% CI.

C-D. Receiver operating characteristic (ROC) curves for the antibody responses to single antigens for individual antigens, and for the SL models (shown in both as binary outcomes of seropositivity / prediction values).

E-F. Variable importance of the 8 Pf-specific (E) and 6 Pv-specific (F) antigens based on the Random Forest model.

G. Predicted rates of recent Pf exposure based on analysis of the continuous antibody responses of the 8-antigen panel using Super Learner. Each hollow dot represents differences in the number of covariates used for the model (3, 4, 8, 9), as well as 2 showing rates from prediction values of the Random Forests (RF) component model (RF.covar4 and RF.covar8 in solid dots).

H. Predicted rates of recent Pv exposure based on analysis of the continuous antibody responses of the 6-antigen panel using Super Learner. Dots represent the positivity rates from the prediction

medRxiv preprint doi: https://doi.org/10.1101/2022.06.16.22276488; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

values of the SL model, and the individual predictions from the 2 most weighted base learners in the resulting model – RF and GBM. RF predictions (RF.covar6) are shown as solid dots. (SL: Super Learner, RF: random Forest, covar#: number of covariates included in the model, FMM: finite mixture models; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 with significance assessed by one-way ANOVA followed by Tukey's multiple comparison)

Figure 5. Seroconversion curves based on reverse catalytic models using AMA1 and MSP1$_{19}$ antibody responses provide accurate estimates of historical exposure.
Age-specific seroprevalence was based on finite mixture models and Random Forest models (using both antigens: RF 2-covar models) for each species. Solid lines represent the fit of the reversible catalytic models, dashed lines represent 95% confidence intervals, and dots represent the observed proportions of seropositives per age divided into 10% centiles. For models assuming a change point in transmission, only the recent seroconversion rates and change point estimates (in years) are shown, while the historical seroconversion rates and seroreversion rates are detailed in Table 4.

Figure 6. Cumulative exposure markers confirm historical *P. falciparum* and *P. vivax* exposure, and heterogeneity of transmission in the 3 sites

A. Plot of Super Learner prediction values for Pf historical exposure by site and age, using the model with 8 Pf-specific serological markers as covariates. Red dotted line represents positivity cutoff at 0.5.

B. Variable importance based on the Random Forest model of the 8 Pf-specific antigens and 6 Pv-specific antigens in predicting historical exposure for each species.

C. Distribution of antibody responses to PfAMA1 by site and age of individuals (n=9132). Red dashed line represents the seropositivity cutoff value from the FMM model.

D-E. Summary graphs per age category per site of SL-predicted Pf historical exposure (D) and PfAMA1, PfMSP1 seropositivity rates graphed with estimated historical exposure rates using the Random Forest model with PfAMA1, PfMSP1$_{19}$ as covariates (E).

F. Summary graph of PvAMA1, PvMSP1 seropositivity rates with estimated historical exposure rates using the Random Forest model with PvAMA1, PvMSP1$_{19}$ as covariates seropositivity per age category per site

Supplementary Figure 1. Antibody levels in response to the rest of the *P. falciparum* and *P. vivax* serological markers in the panel, by study site and age group. Statistical difference of overall antibody responses among study sites within age groups were determined using Kruskall-Wallis test and Wilcoxon test for pairwise comparisons. Related to Fig. 1.

Supplementary Figure 2. Antibody responses of malaria-negative and malaria-positive populations (presented as density plots of log10 net MFI values) to the Pf and Pv serological markers in the panel (Pf and Pv diagnosed by microscopy, RDT and/or PCR. Related to Fig. 1.

Supplementary Figure 3. Performances of the individual base learners in the Super Learner ensemble.

A-B) Plots of the assigned weights to each learner included in the Super Learner models for predicting *P. falciparum* (A) and *P. vivax* recent exposure (B), obtained after 20-fold nested cross-validation of the Pf SL-covar8 and Pv SL-covar6 models.

C-D) Receiver operating characteristic (ROC) curves for detecting current Pf (C) and Pv (D) infections in the test dataset (n=9132) using the 8 Pf and 6 Pv antigens as covariates, respectively. (SL.final: final Super Learner model, RF: random Forest, RF.ranger: RF from ranger package, kNN: k-Nearest Neighbor, GBM: generalized boosted models (implementation for BRT: boosted regression trees), SVM:Support Vector Machine, and GLM: Generalized linear models; variation of algorithms with "corP" denotes a feature selection that screens for univariate correlation)